Biogen Inc. (BIIB)

業務介紹

Biogen Inc.是一家專注於發現、開發、製造和提供治療神經和神經退行性疾病的療法的公司。該公司提供TECFIDERA、VUMERITY、AVONEX、PLEGRIDY、TYSABRI和FAMPYRA等治療多發性硬化症（MS）的產品；SPINRAZA用於治療脊髓性肌肉萎縮症；FUMADERM用於治療銀屑病。此外，該公司還提供BENEPALI（etanercept生物類似物，參考ENBREL）、ADUHELM（用於治療阿茲海默症的藥物）、IMRALDI（adalimumab生物類似物，參考HUMIRA）和FLIXABI（infliximab生物類似物，參考REMICADE）。此外，該公司還提供RITUXAN用於治療非何杰金淋巴瘤、慢性淋巴細胞白血病（CLL）、類風濕性關節炎、兩種ANCA相關性血管炎和天疱瘡；RITUXAN HYCELA用於治療非何杰金淋巴瘤和CLL；GAZYVA用於治療CLL和滑膜淋巴瘤；OCREVUS用於治療復發性MS和初發性進行性MS；以及其他抗CD20療法。此外，該公司還開發了BIIB135、BIIB061、BIIB091和BIIB107用於治療MS和神經免疫學；Aducanumab、Lecanemab、BIIB076和BIIB080用於治療阿茲海默症和痴呆；BIIB067、BIIB078、BIIB105、BIIB100和BIIB110用於治療神經肌肉疾病；BIIB124、BIIB094、BIIB118、BIIB101和BIIB122用於治療帕金森病和運動障礙；BIIB125和BIIB104用於治療神經精神病學；Dapirolizumab pegol和BIIB059用於治療免疫相關疾病；BIIB093和BIIB131用於治療急性神經病學；BIIB074用於神經病性疼痛；以及BYOOVIZ、BIIB800和SB15生物類似物，目前處於不同的開發階段。該公司與Acorda Therapeutics, Inc.、Alkermes Pharma Ireland Limited、Denali Therapeutics Inc.、Eisai Co., Ltd.、Genentech, Inc.、Neurimmune SubOne AG、Ionis Pharmaceuticals, Inc.、Samsung Bioepis Co., Ltd.、Sangamo Therapeutics, Inc.和Sage Therapeutics, Inc.等公司有合作和許可協議。Biogen Inc.成立於1978年，總部位於麻薩諸塞州劍橋市。

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

公司網址

https://www.biogen.com